Open AccessRadioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer
Author(s) -
Chung YongSuk,
Sawada Tetsuji,
Kondo Yasuyuki,
Hirayama Koji,
Inui Akimasa,
Yamashita Yoshito,
Nakata Bunzo,
Okamura Terue,
Ochi Hironobu,
Ho Jenny J. L.,
Kim Young S.,
Sowa Michio
Publication year - 1997
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1997.tb00400.x
Subject(s) - pancreatic cancer , pancreatic disease , medicine , cancer , monoclonal antibody , pancreatitis , ca19 9 , pancreas , pathology , adenocarcinoma , lesion , cancer cell , gastroenterology , antibody , immunology
This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111 ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111 In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.